Last $2.22 USD
Change Today +0.04 / 1.83%
Volume 630.6K
BIOL On Other Exchanges
As of 8:10 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

biolase inc (BIOL) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/25/13 - $3.87
52 Week Low
08/14/13 - $1.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOLASE INC (BIOL)

Related News

No related news articles were found.

biolase inc (BIOL) Related Businessweek News

No Related Businessweek News Found

biolase inc (BIOL) Details

BIOLASE, Inc., a biomedical company, develops, manufactures, and markets lasers in dentistry and medicine in the Unites States and internationally. The company offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications. The company also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional printers, as well as provides precision intuitive diagnosis and treatment planning solutions. In addition, it offers medical systems comprising Diolase 10 Diode Laser for therapeutic applications consisting of temporary pain relief; topical heating for the purpose of temporarily relieving minor muscle and joint pain and stiffness, minor arthritis pain, muscle spasm, minor sprains and strains, and minor muscular back pain; temporarily increasing local blood circulation; and temporarily relaxing muscles. Further, the company manufactures and sells disposable products and accessories for laser systems, as well as markets flexible fibers and hand pieces. BIOLASE, Inc. has a strategic agreement with Valam, Inc. to develop, market, and sell office-based laser systems to otolaryngologists. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

220 Employees
Last Reported Date: 03/17/14
Founded in 1984

biolase inc (BIOL) Top Compensated Officers

President, Chief Operating Officer, Chairman ...
Total Annual Compensation: $131.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $205.4K
Vice President of Business Development
Total Annual Compensation: $155.5K
National Sales Manager
Total Annual Compensation: $148.2K
Director of Professional Relations
Total Annual Compensation: $90.1K
Compensation as of Fiscal Year 2013.

biolase inc (BIOL) Key Developments

Biolase, Inc. Approves Certain Amendments to the its Bylaws

On June 26, 2014, the Board of Directors of Biolase, Inc. approved certain amendments to the company’s bylaws, effective immediately upon approval by the Board. The amendments are reflected in the Sixth Amended and Restated Bylaws of the company. The Amended and Restated Bylaws effect changes to the bylaws so as to: provide that, commencing as of the election of directors at the company’s 2014 annual meeting of stockholders, the maximum number of directors shall be decreased from nine to five; modify the indemnification provisions set forth in Article 10, so as to (a) eliminate mandatory indemnification of employees, agents and certain other persons, such that only directors and officers have rights to indemnification under the Amended and Restated Bylaws, (b) eliminate mandatory advancement of expenses for officers, employees, agents and certain other persons, such that only directors have rights to advancement of expenses under the Amended and Restated Bylaws, (c) provide that no director or officer shall have any rights to indemnification under the Amended and Restated Bylaws, and no director shall have any rights to the advancement of expenses under the Amended and Restated Bylaws, in connection with any proceeding (or part thereof) initiated by such director or officer unless such proceeding (or part thereof) was authorized by the Board and (d) provide that any amendment or modification of the indemnification provisions set forth in the Amended and Restated Bylaws shall generally be prospective only and shall not adversely affect any right or protection of any director or officer existing at the time of such amendment; add a new Article 12, (a) specifying Delaware state or federal courts as the exclusive forum for certain types of lawsuits and (b) shifting litigation expenses to the unsuccessful party if such unsuccessful party is a current or former director (or anyone on behalf of any current or former director) (each, a Claiming Director) who, without prior Board approval, asserts any claim or initiates any proceeding against the company or any of its directors or officers other than a claim or proceeding initiated by a Claiming Director for which such Claiming Director is entitled to (i) indemnification under Section 10.1 of the Amended and Restated Bylaws or any agreement with the company or (ii) bring suit under Section 10.1(b) of the Amended and Restated Bylaws; and remove certain inapplicable provisions such as the references to the now-expired Leadership Committee.

BIOLASE, Inc.(NasdaqCM:BIOL) dropped from Russell 2000 Index

BIOLASE, Inc. will be removed from the Russell 2000 Index.

BIOLASE, Inc.(NasdaqCM:BIOL) dropped from Russell 3000 Index

BIOLASE, Inc. will be removed from the Russell 3000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOL:US $2.22 USD +0.04

BIOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $0.61 USD -0.035
Cutera Inc $10.07 USD +0.05
Stereotaxis Inc $3.28 USD -0.03
Uroplasty Inc $2.63 USD -0.02
Vision Sciences Inc/DE $1.07 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLASE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at